Sanofi-Synthelabo unveils 2 new diabetic drugs


Sanofi-Synthelabo (India) Pvt Ltd has launched two drugs for type-2 diabetes patients in India – Lyxumia (lixisenatide) and Zemiglo (gemigliptin). Lyxumia, a non-insulin injectable drug, is approved in over 70 countries and commercially launched in most EU countries, Sanofi-SynthelaboJapan, Brazil and Mexico, a company statement said. The company has filed an application for approval in the U.S..Zemiglo, oral tablet, has been approved in South Korea in 2012 and has had over three years of clinical experience. “The two additions to Sanofi India portfolio is our step forward in developing new solutions for people with type-2 diabetes,” said N.Rajaram, Country Head.



Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top